NOTCH1 and breast cancer: Notably, Notch ligand DLL1+ quiescent bCSCs drive chemoresistance via NFĸB pathway in BC (235), and disease progression in ER+ BC is dependent on DLL1-mediated Notch1 signaling in bCSCs (236).